Immunomodulatory green nanomedicine production, tumor cellular targeting, in vivo biodistributions and preclinical therapeutic efficacy investigations of resveratrolfunctionalized gold and theranostic 198gold nanoparticles
Carregando...
Data
Data de publicação
Autores IPEN
Orientador
Título da Revista
ISSN da Revista
Título do Volume
É parte de
É parte de
É parte de
Journal of Materials Chemistry B
Exportar
Resumo
Prostate cancer remains a major global health concern demanding innovative therapeutic strategies. This
study introduces a novel green nanotechnology approach for the development of a nanomedicine agent,
also referred to as a nano-radiopharmaceutical, which integrates the antitumor and high antioxidant
capacity of resveratrol phytochemical (RESV) with radioactive gold nanoparticles (198AuNPs) for targeted
prostate cancer therapy and diagnostics. The radioactive formulation, RESV–198AuNP, was developed at the
University of Missouri Research Reactor (MURR) using neutron-activated gold-198, which exhibited high
radionuclidic and radiochemical purity. Stability testing in rat serum and saline demonstrated durability of
up to 15 days. In vivo biodistribution studies in CF-1 mice and PC-3 tumor-bearing SCID mice have
provided insights into pharmacokinetics and optimum tumor retention. Intratumoral administration of
RESV–198AuNP in SCID mice demonstrated strong retention within prostate cancer xenografts, suggesting
tumor-specific uptake and retention. This study underscores the potential of RESV–198AuNP as a dualfunctional
nano-radiopharmaceutical for prostate cancer theranostics. By combining resveratrol’s
anticancer properties with the therapeutic and imaging benefits of 198AuNPs, this platform offers a
promising avenue for improving treatment efficacy and enabling real-time therapeutic response
monitoring. This research reveals the potential of RESV as a tumor-targeting agent and introduces a new
perspective of green nanotechnology for dual anti-inflammatory radiosynovectomy as well as for use in
cancer treatment. In-depth in vivo studies on the therapeutic efficacy of intratumorally administered
RESV–198AuNP revealed that over 85% of the injected dose (ID) remained within prostate tumors for up to
24 h. By the fourth week post-treatment, the treated group exhibited a greater than tenfold reduction in
tumor volumes than the control group receiving saline. This study highlights emerging opportunities in
green nanotechnology and introduces a clinically feasible approach to utilize resveratrol as a tumortargeting
agent in oncology, particularly for the application of RESV–198AuNP in cancer treatments.
Como referenciar
SAKR, TAMER M.; THIPE, VELAPHI C.; KATTI, KAVITA K.; WATKINSON, LISA; CARMACK, TERRY; SMITH, CHARLES J.; CUTLER, CATHY; HEGDE, PRAJNA; HEGDE, ANANTKUMAR; LUGAO, ADEMAR B.; KATTI, KATTESH V. Immunomodulatory green nanomedicine production, tumor cellular targeting, in vivo biodistributions and preclinical therapeutic efficacy investigations of resveratrolfunctionalized gold and theranostic 198gold nanoparticles. Journal of Materials Chemistry B, v. 13, n. 27, p. 8038-8050, 2025. DOI: 10.1039/d5tb00815h. Disponível em: https://repositorio.ipen.br/handle/123456789/49366. Acesso em: 04 Mar 2026.
Esta referência é gerada automaticamente de acordo com as normas do estilo IPEN/SP (ABNT NBR 6023) e recomenda-se uma verificação final e ajustes caso necessário.